Analyst consensus rating
Cytek Biosciences Analyst Rating: Buy
CTKB is rated Buy by 4 analysts with a $5.56 target. As of 2026-09-01.
Direct answer
Cytek Biosciences's consensus rating is Buy.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $5.56.
Forecast evidence checked September 1, 2026.
Get free Cytek Biosciences email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $4.78
- Average price target
- $5.56
- High price target
- $7.50
- Low price target
- $4.75
- Low target gap
- -0.6%
- Target upside
- +16.4%
- High target gap
- +56.9%
- Target range width
- 57.5%
- Consensus rating
- Buy
- Analysts
- 4
- Evidence date
- September 1, 2026
- Valid through
- September 8, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Cytek Biosciences?
Cytek Biosciences has a verified Buy consensus. The same dataset has an average price target of $5.56.
How far are Cytek Biosciences's low and high targets from the recorded price?
The low target implies -0.6%, while the high target implies +56.9%.
How many analysts are included in Cytek Biosciences's consensus?
The verified consensus includes 4 analysts.
How is Cytek Biosciences's target upside or downside calculated?
The average target of $5.56 is divided by the recorded price of $4.78, then one is subtracted to produce +16.4%. This does not guarantee a future return.
When was Cytek Biosciences's analyst forecast verified?
The data was verified on 2026-09-01. The dataset is valid through 2026-09-08.